Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Bio-Rad Laboratories A / Equity Bottom-Up

<ul><li>Bio-Rad Laboratories' financial performance for the third quarter of 2025 was characterized by modest revenue growth, constrained by headwinds in various segments.</li><li>The company reported net sales of approximately $653 million, a slight increase from $650 million in the third quarter of 2024 on a reported basis but a 1.7% decrease on a currency-neutral basis.</li><li>This outcome was primarily influenced by challenges in the academic research and biotech funding sectors, which impacted the Life Science segment.</li></ul>

Bio-Rad Laboratories' financial performance for the third quarter of 2025 was characterized by modest revenue growth, constrained by headwinds in various segments.The company reported net sales of approximately $653 million, a slight increase from $650 million in the third quarter of 2024 on a reported basis but a 1.7% decrease on a currency-neutral basis.This outcome was primarily influenced by challenges in the academic research and biotech funding sectors, which impacted the Life Science segment.

Bio-Rad Laboratories Just Supercharged Its PCR Portfolio—Is This a Game-Changer in Oncology?

<ul><li>Bio-Rad Laboratories Inc.'s (Bio-Rad) second quarter of 2025 results reflect a blend of stability and adverse challenges.</li><li>The company reported net sales of approximately $652 million, a 2.1% increase from the previous year on a reported basis, though just a 1% rise when adjusted for currency fluctuations.</li><li>This performance was largely buoyed by robust sales in the Life Sciences segment, particularly in process chromatography and food safety products.</li></ul>

Bio-Rad Laboratories Inc.'s (Bio-Rad) second quarter of 2025 results reflect a blend of stability and adverse challenges.The company reported net sales of approximately $652 million, a 2.1% increase from the previous year on a reported basis, though just a 1% rise when adjusted for currency fluctuations.This performance was largely buoyed by robust sales in the Life Sciences segment, particularly in process chromatography and food safety products.

Bio-Rad Laboratories: Is The Growth in Digital PCR Business Here To Stay?

<ul><li>Bio-Rad Laboratories reported its financial performance for the first quarter of 2025, revealing mixed results influenced by both internal strategies and external economic factors.</li><li>The company's net sales for the quarter were approximately $585 million, representing a 4.2% decline from $611 million in the same period last year.</li><li>On a currency-neutral basis, this reflected a 1.5% year-over-year decrease.</li></ul>

Bio-Rad Laboratories reported its financial performance for the first quarter of 2025, revealing mixed results influenced by both internal strategies and external economic factors.The company's net sales for the quarter were approximately $585 million, representing a 4.2% decline from $611 million in the same period last year.On a currency-neutral basis, this reflected a 1.5% year-over-year decrease.

Bio-Rad Laboratories Faces Tariff Turmoil—Can Surcharges and Supply Shifts Save Margins?

<ul><li>Bio-Rad Laboratories recently announced its financial results for the fourth quarter and the full fiscal year 2024, revealing both achievements and challenges.</li><li>The company reported net sales of approximately $668 million in the fourth quarter, representing a decline of 2% on a reported basis compared to the same period last year.</li><li>This decrease was largely attributed to a shorter turnaround in the Life Science segment and fluctuations in the biopharma market, notably in China, which still reflected a market downturn.</li></ul>

Bio-Rad Laboratories recently announced its financial results for the fourth quarter and the full fiscal year 2024, revealing both achievements and challenges.The company reported net sales of approximately $668 million in the fourth quarter, representing a decline of 2% on a reported basis compared to the same period last year.This decrease was largely attributed to a shorter turnaround in the Life Science segment and fluctuations in the biopharma market, notably in China, which still reflected a market downturn.

Bio-Rad Laboratories: Expanding In Digital PCR To Strengthen Presence & Advance Molecular Diagnostics!

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>In FY25, <a href="https://www.smartkarma.com/entities/sysmex-corp" target="_blank" data-smartkarma-citation="entities:19333:1" rel="noopener">Sysmex Corp (6869 JP)</a> revenue rose 10% YoY to ¥509B. Operating profit margin expanded 20bps to 17.2%. Amid rising costs, favorable Fx impact of ¥8.6B drove the margin.</li>
<li>Sales grew across regions as instrument installed increased and use of reagents multiplied. America’s volatile margin is a concern, amid the fact that Japan remains the major margin contributor.</li>
<li>For FY26, Sysmex has guided for revenue of ¥535B (+5% YoY). The company has factored in the impact of tariff estimating annual cost of sales impact of approximately ¥3B-4B.</li>
</ul>


In FY25, Sysmex Corp (6869 JP) revenue rose 10% YoY to ¥509B. Operating profit margin expanded 20bps to 17.2%. Amid rising costs, favorable Fx impact of ¥8.6B drove the margin.
Sales grew across regions as instrument installed increased and use of reagents multiplied. America’s volatile margin is a concern, amid the fact that Japan remains the major margin contributor.
For FY26, Sysmex has guided for revenue of ¥535B (+5% YoY). The company has factored in the impact of tariff estimating annual cost of sales impact of approximately ¥3B-4B.


Sysmex Corp (6869 JP): Forex to Take Some Sheen Away off Growth in FY26; Japan Still Remains Key

United States

Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research products, clinical diagnostics, and analytical instrumentation.  The Company's products and systems separate complex chemical and biological materials, as well as identify, analyze, and purify their components.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bio-Rad Laboratories A (BIO US)

Bio-Rad Laboratories Just Supercharged Its PCR Portfolio—Is This a Game-Changer in Oncology?

Bio-Rad Laboratories' financial performance for the third quarter of 2025 was characterized by modest revenue growth, constrained by headwinds in...

Baptista Research

Bio-Rad Laboratories: Is The Growth in Digital PCR Business Here To Stay?

Bio-Rad Laboratories Inc.'s (Bio-Rad) second quarter of 2025 results reflect a blend of stability and adverse challenges. The company reported net...

Baptista Research

Bio-Rad Laboratories Faces Tariff Turmoil—Can Surcharges and Supply Shifts Save Margins?

Bio-Rad Laboratories reported its financial performance for the first quarter of 2025, revealing mixed results influenced by both internal...

Baptista Research

Bio-Rad Laboratories: Expanding In Digital PCR To Strengthen Presence & Advance Molecular Diagnostics!

Bio-Rad Laboratories recently announced its financial results for the fourth quarter and the full fiscal year 2024, revealing both achievements...

Baptista Research

Sysmex Corp (6869 JP): Forex to Take Some Sheen Away off Growth in FY26; Japan Still Remains Key

Sysmex's FY25 revenue increased 10% to ¥509B with expanding profit margin. However, concern remains over America's volatile margin. The company...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Bio-Rad Laboratories Just Supercharged Its PCR Portfolio—Is This a Game-Changer in Oncology?

Bio-Rad Laboratories' financial performance for the third quarter of 2025 was characterized by modest revenue growth, constrained by headwinds in...

Baptista Research

Bio-Rad Laboratories: Is The Growth in Digital PCR Business Here To Stay?

Bio-Rad Laboratories Inc.'s (Bio-Rad) second quarter of 2025 results reflect a blend of stability and adverse challenges. The company reported net...

Baptista Research

Bio-Rad Laboratories Faces Tariff Turmoil—Can Surcharges and Supply Shifts Save Margins?

Bio-Rad Laboratories reported its financial performance for the first quarter of 2025, revealing mixed results influenced by both internal...

Baptista Research

Bio-Rad Laboratories: Expanding In Digital PCR To Strengthen Presence & Advance Molecular Diagnostics!

Bio-Rad Laboratories recently announced its financial results for the fourth quarter and the full fiscal year 2024, revealing both achievements...

Baptista Research

Sysmex Corp (6869 JP): Forex to Take Some Sheen Away off Growth in FY26; Japan Still Remains Key

​Sysmex's FY25 revenue increased 10% to ¥509B with expanding profit margin. However, concern remains over America's volatile margin. The company...

Tina Banerjee

Sysmex's FY25 revenue increased 10% to ¥509B with expanding profit margin. However, concern remains over America's volatile margin. The company...